Coeptis Therapeutics Inc. (NASDAQ: COEP), a pre-clinical stage biopharmaceutical Corp, announced an exclusive term sheet (expires 31 Aug 23) to acquire or license Deverra Therapeutics’ platform asset onto which COEP’s SNAP-CAR and GEAR platforms could ‘dovetail’ and create a potentially very broad application set of immune technologies. Deverra’s proprietary allogeneic stem cell platform side steps patient donor matching to produce a broad range of immune effector cells, which can kill cancer and pathogen infected cells. COEP SNAP-CAR products could plug into Deverra’s effector cells. According to Deverra, its platform has been in clinical operation since 2006. If this deal is executed, it has the potential to significantly broaden applications for COEP’s SNAP-CAR (‘universal wrench’) and GEAR platforms.
21 Apr 2023
Coeptistx (COEP) Deverra Deal Flash Note ACF Equity Research 20042023
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Coeptistx (COEP) Deverra Deal Flash Note ACF Equity Research 20042023
- Published:
21 Apr 2023 -
Author:
ACF Analyst Team -
Pages:
8
Coeptis Therapeutics Inc. (NASDAQ: COEP), a pre-clinical stage biopharmaceutical Corp, announced an exclusive term sheet (expires 31 Aug 23) to acquire or license Deverra Therapeutics’ platform asset onto which COEP’s SNAP-CAR and GEAR platforms could ‘dovetail’ and create a potentially very broad application set of immune technologies. Deverra’s proprietary allogeneic stem cell platform side steps patient donor matching to produce a broad range of immune effector cells, which can kill cancer and pathogen infected cells. COEP SNAP-CAR products could plug into Deverra’s effector cells. According to Deverra, its platform has been in clinical operation since 2006. If this deal is executed, it has the potential to significantly broaden applications for COEP’s SNAP-CAR (‘universal wrench’) and GEAR platforms.